Phage display connects antibody phenotype with its encoding sequence, enabling large repertoires to be screened under controlled in vitro selection conditions. Creative Biolabs configures each project around the target format, intended pet species, required antibody architecture, desired mechanism, assay readiness, and downstream development plan. Programs may begin with a premade canine or feline repertoire, a custom naïve, immune, or synthetic library, or an existing enriched pool that requires screening and sequence recovery.
Our stage-gated workflow combines antigen and selection strategy, enrichment monitoring, monoclonal screening, sequence clustering, antibody reformatting, production, and early characterization. Counter-selection, solution-phase selection, cell-based panning, competitive elution, and functional screening can be incorporated when target biology or specificity requirements demand a more tailored campaign.
Choose rapid screening from an established species-specific repertoire or build a purpose-designed library when the target, species, immunization history, diversity architecture, or selection challenge requires a customized solution.
Screen established, high-diversity canine or feline phage display libraries against a qualified target to identify species-matched antibody fragments without first constructing a new repertoire.
Design and construct a naïve, immune, or synthetic phage display library using selected biological sources, veterinary species sequences, antibody formats, and engineered diversity profiles, followed by target-specific screening.
The workflow is configured around antigen behavior and project decisions rather than a fixed protocol. Estimated timing begins after required materials and assays are ready and may change with library construction, target complexity, screening stringency, and reformatting scope.
Select a premade repertoire or construct a naïve, immune, or synthetic library. Review antigen quality, presentation format, controls, and screening assay suitability.
Perform iterative binding, washing, elution, bacterial amplification, and re-selection. Apply counter-selection or adjusted stringency to improve target-focused enrichment.
Isolate individual clones and screen by phage ELISA, soluble-fragment assays, flow cytometry, competition, or other fit-for-purpose methods.
Recover variable-region sequences, cluster unique families, assess sequence liabilities, and reformat prioritized scFv or Fab fragments into canine, feline, or other requested formats.
Express and purify selected antibodies, then compare binding, specificity, apparent affinity, purity, aggregation, and target-relevant activity as defined in the study plan.
Advance selected molecules through affinity maturation, sequence optimization, format conversion, or Fc engineering with re-screening to confirm retained function.
Receive a consolidated report, methods, screening and characterization data, unique lead sequences, and agreed quantities of purified lead material.
| Discovery Decision | Available Approaches | Typical Data Generated | How It Supports Selection |
|---|---|---|---|
| Antigen presentation | Immobilized protein or peptide, biotinylated antigen, cells, membrane-associated targets, or competitive formats. | Enrichment trends, target binding, control binding, and assay performance. | Helps preserve relevant epitopes and reduce selection artifacts. |
| Specificity control | Negative antigens, orthologs, homologous family members, non-target cells, matrix controls, or depletion steps. | Counter-screen profiles and cross-reactivity comparisons. | Removes broadly reactive or context-dependent binders earlier. |
| Hit differentiation | Monoclonal ELISA, flow cytometry, competition assays, SPR/BLI, cell-based activity, or functional screening. | Binding rank, specificity, kinetic estimates, competition, and functional evidence. | Separates simple binders from candidates aligned with the intended mechanism. |
| Molecule format | scFv, Fab, canine IgG, feline IgG, Fc-fusion, or other requested architecture. | Expression, purity, binding retention, and early biophysical observations. | Confirms whether activity is maintained after conversion to a development-relevant format. |
Our scientists can recommend a premade-library campaign, custom library strategy, or focused screening module after reviewing antigen format, assay readiness, desired antibody format, and selection criteria.
Our canine and feline platforms provide species-relevant repertoires and discovery workflows for pet therapeutic antibody research. Final candidate quality still depends on target biology, selection design, clone properties, and downstream validation.
CynoCure™ supports canine antibody discovery using diverse canine-oriented repertoires and species-aware screening and reformatting strategies. Starting from canine framework content can reduce the amount of later species-adaptation work, while sequence analysis, specificity testing, functional assays, and developability assessment remain important for candidate qualification.
Learn About CynoCure™
FeliCure™ is configured for feline therapeutic antibody research using feline-relevant repertoire design, selection, sequence review, and full-length reformatting. The platform can support challenging targets through adjusted panning and screening strategies while keeping feline constant-region and downstream assay requirements in view.
Learn About FeliCure™Bashir and Paeshuyse summarized the construction and selection of antibody phage libraries for veterinary immunovirology. The illustrated biopanning cycle shows antigen presentation, incubation with a diverse antibody-displaying phage pool, removal of unbound or weakly bound clones, recovery of retained phage, bacterial amplification, and repeated selection to enrich target-focused binders.1,2
The study highlights technical elements that directly inform pet antibody discovery planning, including scFv and Fab library construction, large repertoire screening, iterative selection pressure, antigen-format choices, enrichment, clone recovery, and downstream characterization. Creative Biolabs applies these principles through premade or custom library services, tailored panning, monoclonal screening, sequence analysis, species-specific reformatting, and preliminary lead evaluation.
Integrated technical planning helps align library choice, selection pressure, hit screening, species format, and downstream evidence with the decisions your program needs to make.
Premade, naïve, immune, and synthetic strategies fit different targets and species.
Enrichment, counter-screens, sequence diversity, and function guide candidate decisions.
Canine and feline formats connect discovery fragments with relevant downstream studies.
Methods, sequences, screening data, purified leads, and conclusions support transfer.